2021 regulatory trends in China, including antitrust, data privacy, sanctions, healthcare, PE/VC, capital markets, IP, banking & finance, TMT and arbitration.
Aggie Liu, Binxin Li, Yun Chen and Muzi Xuan of FenXun Partners, highlight China's 2021 legislative and enforcement developments in the intellectual property sector including how they respond to challenges posed by emerging technologies and stimulate innovative vitality, significant cases that strengthen IP protection mechanisms and standards, and what the future holds for IP in 2022
Ting Wu of Haiwen & Partners reviews the regulatory reforms taking place in China's life science and healthcare sector including legislation that has been released to encourage innovation and broaden market access to drugs, implementation of the patent linkage system, increasing antitrust enforcement pressure in the pharma sector, regulating medical devices, cosmetics and online hospitals.
Luka Groselj of Schellenberg Wittmer and Runyang Liu of Zhong Lun Law Firm provide practical guidance on contract drafting and performance to overcome possible non-signatory issues and how to navigate the current laws and court decisions when encountering such an issue
Luka Groselj of Schellenberg Wittmer and Runyang Liu of Zhong Lun Law Firm compare the legal principles and exceptions to the extension of arbitration agreements to non-signatories under Chinese and Swiss legal frameworks including succession, transfer, performance, guarantee, and subrogation and when the non-signatory may be bound by arbitration agreements
